Published in CA Cancer J Clin on March 03, 2010
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Prognostic indices for older adults: a systematic review. JAMA (2012) 5.70
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol (2014) 2.32
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol (2015) 2.29
External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc (2011) 2.20
Informed Decision-Making and Breast Cancer Screening. J Med Screen (2015) 2.09
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. Health Aff (Millwood) (2013) 1.63
Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur Urol (2013) 1.54
A Randomized Controlled Effectiveness Trial for PSA Screening Decision Support Interventions in Two Primary Care Settings. J Gen Intern Med (2015) 1.43
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer (2012) 1.38
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. Can Urol Assoc J (2012) 1.32
Risk prediction of complex diseases from family history and known susceptibility loci, with applications for cancer screening. Am J Hum Genet (2011) 1.26
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Informed decision making about prostate cancer testing in predominantly immigrant black men: a randomized controlled trial. Ann Behav Med (2012) 1.12
Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. J Nanopart Res (2011) 1.12
National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med (2013) 1.11
Discussions about prostate cancer screening between U.S. primary care physicians and their patients. J Gen Intern Med (2011) 1.11
Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials. J Natl Cancer Inst (2013) 1.09
Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med (2012) 1.08
Primary care physicians' use of an informed decision-making process for prostate cancer screening. Ann Fam Med (2013) 1.08
Updating risk prediction tools: a case study in prostate cancer. Biom J (2011) 1.08
Prostate-specific antigen-based screening: controversy and guidelines. BMC Med (2015) 1.08
Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag Sci (2012) 1.06
Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One (2012) 1.06
What is lacking in current decision aids on cancer screening? CA Cancer J Clin (2013) 1.06
Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy. Indian J Med Res (2014) 1.06
Patient-centered discussions about prostate cancer screening: a real-world approach. Ann Intern Med (2010) 1.05
African American men's and women's perceptions of clinical trials research: focusing on prostate cancer among a high-risk population in the South. J Health Care Poor Underserved (2013) 1.03
It takes two to talk about prostate cancer: a qualitative assessment of African American men's and women's cancer communication practices and recommendations. Am J Mens Health (2012) 1.02
The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci (2012) 1.01
Introducing the 2010 American Cancer Society prostate cancer screening guideline. CA Cancer J Clin (2010) 0.99
What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med (2010) 0.99
A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia. Radiol Oncol (2011) 0.97
Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. PLoS One (2012) 0.96
The cost implications of prostate cancer screening in the Medicare population. Cancer (2013) 0.95
Feasibility Study of Engaging Barbershops for Prostate Cancer Education in Rural African-American Communities. J Cancer Educ (2015) 0.93
Prostate cancer incidence in males with Lynch syndrome. Genet Med (2014) 0.92
Commentary: eight ways to prevent cancer: a framework for effective prevention messages for the public. Cancer Causes Control (2012) 0.92
Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications. Oncol Lett (2015) 0.91
Family and friend interactions among African-American men deciding whether or not to have a prostate cancer screening. Urol Nurs (2010) 0.91
To be screened or not to be screened? Modeling the consequences of PSA screening for the individual. Br J Cancer (2012) 0.90
Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med (2014) 0.90
Prostate cancer deaths and incident cases among American Indian/Alaska Native men, 1999-2009. Am J Public Health (2014) 0.89
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate (2011) 0.89
Reversals of association for Pap, colorectal, and prostate cancer testing among Hispanic and non-Hispanic black women and men. Cancer Epidemiol Biomarkers Prev (2011) 0.89
Prostate cancer screening: Attitudes and practices of family physicians in Ontario. Can Urol Assoc J (2012) 0.88
H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples. Biomark Insights (2011) 0.88
Shared decision making for prostate cancer screening: the results of a combined analysis of two practice-based randomized controlled trials. BMC Med Inform Decis Mak (2012) 0.87
Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. Curr Opin Oncol (2013) 0.87
Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring. J Natl Cancer Inst Monogr (2012) 0.87
The influence of stress, depression, and anxiety on PSA screening rates in a nationally representative sample. Med Care (2012) 0.87
Incidental Focal (18)F-FDG Uptake in the Prostate: Clinical Significance and Differential Diagnostic Criteria. Nucl Med Mol Imaging (2011) 0.86
American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin (2015) 0.86
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor. Biosensors (Basel) (2012) 0.86
PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr) (2016) 0.86
Fully Automated Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Fusion via a Probabilistic Registration Metric. Proc SPIE Int Soc Opt Eng (2013) 0.85
Reconciling primary care and specialist perspectives on prostate cancer screening. Ann Fam Med (2012) 0.85
What do the screening trials really tell us and where do we go from here? Urol Clin North Am (2014) 0.84
Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review. Ann Lab Med (2013) 0.83
Correlates of colorectal cancer screening adherence among men who have been screened for prostate cancer. J Cancer Educ (2011) 0.83
Optimal baseline prostate-specific antigen level to distinguish risk of prostate cancer in healthy men between 40 and 69 years of age. J Korean Med Sci (2011) 0.83
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. World J Urol (2012) 0.83
Personalized medicine in screening for malignant disease: a review of methods and applications. Biomark Insights (2013) 0.83
Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis. BMJ Open (2014) 0.82
Translating medical evidence to promote informed health care decisions. Health Serv Res (2011) 0.82
Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. Int J Clin Exp Pathol (2013) 0.82
Genes, race, and culture in clinical care: racial profiling in the management of chronic illness. Med Anthropol Q (2013) 0.82
Impact of health system challenges on prostate cancer control: health care experiences in Nigeria. Infect Agent Cancer (2011) 0.82
Physician behaviors to promote informed decisions for prostate cancer screening: a National Research Network study. J Cancer Educ (2014) 0.81
Prostatic carcinoma bilateral iris metastases. Bosn J Basic Med Sci (2012) 0.81
Getting Black Men to Undergo Prostate Cancer Screening: The Role of Social Capital. Am J Mens Health (2014) 0.81
Can 3T multiparametric magnetic resonance imaging accurately detect prostate cancer extracapsular extension? Can Urol Assoc J (2013) 0.81
A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU Int (2014) 0.81
Shared decision making in prostate-specific antigen testing with men older than 70 years. J Am Board Fam Med (2013) 0.80
A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol (2012) 0.80
Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies. Int J Cancer (2016) 0.80
Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals? Eur J Epidemiol (2016) 0.79
Perceptions of prostate cancer fatalism and screening behavior between United States-born and Caribbean-born Black males. J Immigr Minor Health (2014) 0.79
Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening. BMC Cancer (2011) 0.79
Remaining Life Expectancy Measurement and PSA Screening of Older Men. J Geriatr Oncol (2012) 0.79
Physicians' anxiety due to uncertainty and use of race in medical decision making. Med Care (2014) 0.79
Multiattribute probabilistic prostate elastic registration (MAPPER): application to fusion of ultrasound and magnetic resonance imaging. Med Phys (2015) 0.79
Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review. EBioMedicine (2016) 0.78
Management of the asymptomatic BRCA mutation carrier. Appl Clin Genet (2010) 0.78
PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. Asian J Androl (2011) 0.78
What we have learned from randomized trials of prostate cancer screening. Asian J Androl (2011) 0.78
A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Med Inform Decis Mak (2013) 0.78
MRI-guided core biopsy of the prostate in the supine position--introduction of a simplified technique using large-bore magnet systems. Eur Radiol (2012) 0.78
Prostate cancer risk prediction in a urology clinic in Mexico. Urol Oncol (2012) 0.78
Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther (2014) 0.78
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin (2008) 12.90
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res (2007) 5.60
Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA (2013) 5.56
American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin (2002) 5.56
Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet (2003) 5.40
Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin (2007) 5.31
Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology (2011) 5.17
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen (2010) 4.72
Worldwide variations in colorectal cancer. CA Cancer J Clin (2009) 4.71
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin (2012) 4.32
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin (2014) 3.59
Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. Chest (2004) 3.55
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin (2006) 3.21
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med (2005) 3.01
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer (2005) 2.91
Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation (2004) 2.91
The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer (2002) 2.85
The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg (2005) 2.83
Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc (2007) 2.82
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Counterpoint: Overdiagnosis in breast cancer screening. J Am Coll Radiol (2014) 2.75
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients. Med Care (2008) 2.48
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol (2012) 2.45
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer (2008) 2.41
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs. Breast J (2014) 2.37
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat (2008) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer (2008) 2.28
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med (2010) 2.17
Invited commentary: genes, environment, and hybrid vigor. Am J Epidemiol (2009) 2.15
Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers. Hum Pathol (2013) 2.09
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One (2008) 2.07
Identifying minimally acceptable interpretive performance criteria for screening mammography. Radiology (2010) 2.06
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology (2013) 2.06
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Correlates of underutilization of colorectal cancer screening among U.S. adults, age 50 years and older. Prev Med (2003) 2.05
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
[Patients forgoing health care for economic reasons: how to identify this in a primary care setting?]. Rev Med Suisse (2014) 2.00
Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin (2014) 1.95
The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol (2006) 1.91
Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer (2008) 1.90
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol (2012) 1.89
Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology (2006) 1.89
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Modelling the cumulative risk of a false-positive screening test. Stat Methods Med Res (2010) 1.87
Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer (2002) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J (2006) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Influence of annual interpretive volume on screening mammography performance in the United States. Radiology (2011) 1.81
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78